OTCPK:BIOYF (Canada) Also trade in: Canada

Biosyent Inc

$ 6.04 0.01 (0.18%)
Volume: 200 Avg Vol (1m): 6,846
Market Cap $: 85.26 Mil Enterprise Value $: 67.01 Mil
P/E (TTM): 20.90 P/B: 4.28
Earnings Power Value 4.14
Net Current Asset Value 1.27
Tangible Book 1.31
Projected FCF 4.03
Median P/S Value 5.78
Graham Number 2.92
Peter Lynch Value 5.44
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
97.67% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
BIOYF: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.15, Med: 10000, Max: 10000
Current: 10000
0.15
10000
Equity-to-Asset 0.89
Equity-to-Asset ranked higher than
91.75% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
BIOYF: 0.89
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.18, Med: 0.78, Max: 0.89
Current: 0.89
0.18
0.89
Interest Coverage No Debt
Interest Coverage ranked higher than
97.53% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
BIOYF: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 14.38, Med: 10000, Max: 10000
Current: 10000
14.38
10000
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 22.55
DISTRESS
GREY
SAFE
Beneish M-Score -2.67
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 141.51%
WACC 2.51%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 31.26
Operating Margin ranked higher than
93.51% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
BIOYF: 31.26
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -27.38, Med: 31.43, Max: 33.56
Current: 31.26
-27.38
33.56
Net Margin % 26.50
Net Margin ranked higher than
91.40% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
BIOYF: 26.5
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -25.34, Med: 24.6, Max: 30.67
Current: 26.5
-25.34
30.67
ROE % 22.82
ROE ranked higher than
91.35% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
BIOYF: 22.82
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -35.73, Med: 33.46, Max: 77.01
Current: 22.82
-35.73
77.01
ROA % 20.39
ROA ranked higher than
96.67% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
BIOYF: 20.39
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -27.71, Med: 27.64, Max: 58.84
Current: 20.39
-27.71
58.84
ROC (Joel Greenblatt) % 443.16
ROC (Joel Greenblatt) ranked higher than
98.95% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
BIOYF: 443.16
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -236.97, Med: 590.65, Max: 2618.53
Current: 443.16
-236.97
2618.53
3-Year Total Revenue Growth Rate 11.80
3-Year Revenue Growth Rate ranked higher than
82.44% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
BIOYF: 11.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -15.5, Med: 14.5, Max: 63
Current: 11.6
-15.5
63
3-Year Total EBITDA Growth Rate 10.90
3-Year EBITDA Growth Rate ranked higher than
67.90% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
BIOYF: 10.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 10.6, Max: 158.1
Current: 10.6
0
158.1
3-Year EPS w/o NRI Growth Rate 14.50
3-Year EPS w/o NRI Growth Rate ranked higher than
65.16% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
BIOYF: 14.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 94.3
Current: 14.5
0
94.3

» BIOYF's 30-Y Financials

Financials (Next Earnings Date: 2019-05-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:BIOYF

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 3741
Compare XCNQ:CHOO ROCO:4191 NAS:ATXI ROCO:6496 TSXV:EVE TSE:4524 LSE:SIS NAS:SCYX CAS:PRO XKRX:080720 HKSE:00574 ASX:AC8 OTCPK:ELTP XCNQ:TGIF NAS:VERU ROCO:6539 BSE:BIO XCNQ:WRLD.U BOM:531146 NEOE:HALO
Traded in other countries RX.Canada
Address 170 Attwell Drive, Suite 520, Toronto, ON, CAN, M9W 5Z5
Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products. Geographically all the activities are functioned through the region of Canada.

Ratios

Current vs industry vs history
PE Ratio (TTM) 20.90
PE Ratio ranked lower than
51.89% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
BIOYF: 20.9
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 3.91, Med: 26.19, Max: 99999999.99
Current: 20.9
3.91
99999999.99
Forward PE Ratio 18.52
Forward P/E ranked lower than
56.76% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
BIOYF: 18.52
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 20.90
PE without NRI ranked lower than
51.44% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
BIOYF: 20.9
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 3.91, Med: 26.19, Max: 99999999.99
Current: 20.9
3.91
99999999.99
Price-to-Owner-Earnings 21.85
Price-to-Owner-Earnings ranked higher than
61.42% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
BIOYF: 21.85
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 5, Med: 26.06, Max: 190
Current: 21.85
5
190
PB Ratio 4.28
PB Ratio ranked lower than
79.73% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
BIOYF: 4.28
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.29, Med: 5.51, Max: 23.88
Current: 4.28
0.29
23.88
PS Ratio 5.51
PS Ratio ranked lower than
73.16% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
BIOYF: 5.51
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.22, Med: 5.27, Max: 16.35
Current: 5.51
0.22
16.35
Price-to-Free-Cash-Flow 20.48
Price-to-Free-Cash-Flow ranked higher than
61.41% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
BIOYF: 20.48
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.14, Med: 24.84, Max: 61.41
Current: 20.48
7.14
61.41
Price-to-Operating-Cash-Flow 18.82
Price-to-Operating-Cash-Flow ranked higher than
52.55% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
BIOYF: 18.82
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.12, Med: 22.77, Max: 63.33
Current: 18.82
4.12
63.33
EV-to-EBIT 13.45
EV-to-EBIT ranked higher than
50.35% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
BIOYF: 13.45
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -6.5, Med: 14.05, Max: 47.2
Current: 13.45
-6.5
47.2
EV-to-EBITDA 13.09
EV-to-EBITDA ranked lower than
56.62% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
BIOYF: 13.09
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -6.8, Med: 13.7, Max: 46.6
Current: 13.09
-6.8
46.6
EV-to-Revenue 4.20
EV-to-Revenue ranked lower than
67.92% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
BIOYF: 4.2
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.5, Med: 4.3, Max: 15.8
Current: 4.2
-0.5
15.8
PEG Ratio 1.00
PEG Ratio ranked higher than
80.44% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
BIOYF: 1
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.25, Med: 0.66, Max: 1.21
Current: 1
0.25
1.21
Shiller PE Ratio 42.30
Shiller PE Ratio ranked lower than
76.98% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
BIOYF: 42.3
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 39.47, Med: 83.23, Max: 685
Current: 42.3
39.47
685
Current Ratio 8.82
Current Ratio ranked higher than
92.05% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
BIOYF: 8.82
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.28, Med: 4.3, Max: 8.82
Current: 8.82
0.28
8.82
Quick Ratio 8.36
Quick Ratio ranked higher than
92.28% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
BIOYF: 8.36
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.21, Med: 3.84, Max: 8.36
Current: 8.36
0.21
8.36
Days Inventory 98.16
Days Inventory ranked higher than
63.44% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
BIOYF: 98.16
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 54.36, Med: 95.89, Max: 167.97
Current: 98.16
54.36
167.97
Days Sales Outstanding 34.57
Days Sales Outstanding ranked higher than
84.81% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
BIOYF: 34.57
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 18.68, Med: 36.48, Max: 62.1
Current: 34.57
18.68
62.1
Days Payable 204.87
Days Payable ranked higher than
82.98% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
BIOYF: 204.87
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 172.61, Med: 212.45, Max: 271.43
Current: 204.87
172.61
271.43

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.20
3-Year Share Buyback Rate ranked higher than
70.23% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
BIOYF: -1.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -14.2, Med: -2, Max: -0.1
Current: -1.2
-14.2
-0.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.61
Price-to-Tangible-Book ranked lower than
74.37% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
BIOYF: 4.61
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.37, Med: 3.83, Max: 30
Current: 4.61
0.37
30
Price-to-Projected-FCF 1.50
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
50.27% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
BIOYF: 1.5
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.48, Med: 2.92, Max: 6.91
Current: 1.5
1.48
6.91
Price-to-Median-PS-Value 1.04
Price-to-Median-PS-Value ranked lower than
87.75% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
BIOYF: 1.04
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.08, Med: 0.48, Max: 2.68
Current: 1.04
0.08
2.68
Price-to-Peter-Lynch-Fair-Value 1.11
Price-to-Peter-Lynch-Fair-Value ranked higher than
66.51% of 212 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
BIOYF: 1.11
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.17, Med: 1.08, Max: 1.1
Current: 1.11
0.17
1.1
Price-to-Graham-Number 2.07
Price-to-Graham-Number ranked lower than
70.48% of 481 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
BIOYF: 2.07
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.07, Med: 2.05, Max: 7.08
Current: 2.07
0.07
7.08
Earnings Yield (Joel Greenblatt) % 7.43
Earnings Yield (Greenblatt) ranked higher than
67.24% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
BIOYF: 7.43
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -242, Med: 5.5, Max: 33333.3
Current: 7.43
-242
33333.3
Forward Rate of Return (Yacktman) % 22.37
Forward Rate of Return ranked higher than
93.82% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
BIOYF: 22.37
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -3.3, Med: 2.9, Max: 23.5
Current: 22.37
-3.3
23.5

More Statistics

Revenue (TTM) (Mil) $ 16.38
EPS (TTM) $ 0.3
Beta 0.01
Volatility % 27.49
52-Week Range $ 4.84 - 7.98
Shares Outstanding (Mil) 14.1

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N